Top 5 Jefferies Big Pharma Stock Picks for Q4
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
After Fluidigm announced preliminary results for its third quarter on Wednesday, investors sent the shares sharply lower.
Ocular Therapeutix and Regeneron are attempting to develop a sustained release formulation of aflibercept that is suitable for advancement into clinical development.
Shares of IntelliPharmaCeutics soared after the company reported a new licensing deal with Mallinckrodt.
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.
Accelerated Pharma intends to price less than 2 million shares in the range of $8 to $10 for an initial public offering valued up to more than $21 million.
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.
Biostar Pharmaceuticals Inc. (NASDAQ: BSPM) is watching its shares nearly double on Tuesday after the company announced that it is releasing a new product line to treat respiratory irritation and inflammation. Specifically, Biostar is launching…
Nymox Pharmaceutical shares jumped following the announcement of positive results from its late-stage prostate cancer trial.
KemPharm shares saw a solid gain on Tuesday following a key FDA approval on it treatment for attention deficit hyperactivity disorder.
Merrimack Pharmaceuticals shares saw a handy gain early Tuesday after the company announced positive results for its late stage metastatic pancreatic cancer study.
When Illumina issued an update on its sales for the third quarter, the numbers came in below what analysts were looking for, and as a result investors sent the stock lower.
Mazor Robotics Ltd. (NASDAQ: MZOR) is watching its shares rise handily on Monday after the company announced that it has received the first pre-launch orders for its guidance platform for spine surgeries. The Mazor X…
IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) is watching its shares jump on Monday after the company announced that it received a tentative approval from the U.S. Food and Drug Administration. Specifically, the tentative approval was…